Evidence map›Paper›PMID 33111255›Full record

ArticleAdvances in therapy2021

Adherence to the Sociedad Española de Oncología Médica (SEOM) Algorithm for the Treatment of Hyponatremia in Oncology Patients in Spain: The ALGA Study.

Fernando Henao, Aranzazu Manzano, Rafael Lopez Lopez, Ana Luisa Gobartt, Ramón de Las Peñas

Abstract read
PubMed Publisher
In one paragraph

Article in Advances in therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 77% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 1 country.

Fernando HenaoMedical Oncology Department, Hospital Universitario Virgen Macarena, Calle Dr. Fedriani, 3, 41009, Seville, Spain.ORCID http://orcid.org/0000-0003-3819-9572
Aranzazu ManzanoService of Medical Oncology, Hospital Clínico San Carlos, Calle del Prof Martín Lagos, s/n, 28040, Madrid, Spain.ORCID http://orcid.org/0000-0001-5694-1801
Rafael Lopez LopezDepartment of Oncology-CIBERONC, Complejo Hospitalario Universitario de Santiago, Rúa da Choupana, s/n, 15706, Santiago de Compostela, Spain.ORCID http://orcid.org/0000-0003-1315-655X
Ana Luisa GobarttMedical Manager Hospital Unit, Otsuka Pharmaceuticals SA, Avenida Diagonal, 615, 08025, Barcelona, Spain.
Ramón de Las PeñasDepartment of Oncology, Consorcio Hospitalario Provincial de Castellón, Avenida Doctor Clara, 19, 12002, Castelló, Spain. ramon.delaspenas@hospitalprovincial.es.ORCID http://orcid.org/0000-0002-2170-4168
Complejo Hospitalario Universitario de Santiago · ESConsorcio Hospitalario Provincial de Castellón · ESHospital Clínico San Carlos · ESHospital Universitario Virgen Macarena · ESOtsuka Pharmaceutical (Spain) · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe ALGA study explored adherence of Spanish treatment centers to the Sociedad Española de Oncología Médica (SEOM) treatment algorithm for oncology patients with hyponatremia that requires treatment as the main cause of hospitalization, and evaluated the impact of adherence to this algorithm on patient outcomes.

methodsThis retrospective study recruited patients aged at least 18 years with cancer, treated for at least one episode of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). The primary outcome was the proportion of patients whose treatment adhered to the SEOM algorithm, evaluated using a pre-defined decision tree. Secondary outcomes included length of hospitalization, and time to serum sodium level improvement. Perceived center adherence to the SEOM algorithm was also assessed.

resultsSeventy patients from four treatment centers were included. Twenty (28.6%; 95% confidence interval [CI] 18.0, 39.2) patients on hyponatremia treatment adhered to the SEOM algorithm, with a perceived adherence of 51.0-75.0%. Algorithm adherence in candidates for chemotherapy was 36.4% (n = 8) versus 25.0% (n = 12) for non-candidates for chemotherapy. Median time to serum sodium level improvement in patients managed adherently was 80.5 h (95% CI 38.3, 331.4) versus 134.6 h (33.2, 444.9) in patients managed non-adherently. Median time to hospital discharge was 16.5 days (95% CI 8.0, 27.0) in patients managed adherently versus 9.5 days (7.0, 22.0) in patients managed non-adherently.

conclusionIn Spanish centers, the SEOM algorithm was adhered to in less than one-third of patients, in contrast to higher levels of perceived adherence. This requires further investigation; however, algorithm use could require further clarification, especially in non-candidates for chemotherapy.

Indexed as

HyponatremiaNeoplasmsAdolescentAdultAlgorithmsHumansRetrospective StudiesSpainCancerChemotherapyHyponatremiaOncologySupportive careTolvaptanTreatment algorithm

Identifiers

PMID33111255
OpenAlexW3097070435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.